New treatments addressing the pathophysiology of hereditary angioedema
2008
New Treatments for Hereditary Angioedema
publication
Evidence: moderate
Author Information
Author(s): Davis Alvin E III
Primary Institution: Harvard Medical School
Hypothesis
What are the new treatments addressing the pathophysiology of hereditary angioedema?
Conclusion
Several new therapies for hereditary angioedema are in development, including C1-inhibitor replacement therapies and agents targeting bradykinin.
Supporting Evidence
- Hereditary angioedema is caused by a deficiency of C1-inhibitor.
- Current treatments for acute attacks are ineffective in the U.S.
- Five new agents are in Phase III development targeting the underlying cause of hereditary angioedema.
Takeaway
Hereditary angioedema is a condition that causes painful swelling, and new treatments are being developed to help manage it better.
Methodology
Review of current findings and clinical trials related to hereditary angioedema treatments.
Potential Biases
Financial competing interests disclosed by the author.
Limitations
Current therapies in the U.S. are suboptimal and may lead to significant medical consequences.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website